UTHR vs. VTRS: United Therapeutics vs. Viatris Stock Comparison

November 11, 2026

How do United Therapeutics (UTHR) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

United Therapeutics (UTHR) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but UTHR is classified in Biotechnology while VTRS is classified in Pharmaceuticals.

Company profile comparison for United Therapeutics (UTHR) and Viatris (VTRS)
Profile Item	UTHR	VTRS
Name	United Therapeutics Corporation	Viatris Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Pharmaceuticals
GICS Sub-Industry	Biotechnology	Pharmaceuticals
Market Capitalization	23.94 billion USD	22.83 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	June 17, 1999	March 17, 1980
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

UTHR

VTRS

GSPC

United Therapeutics (UTHR) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for United Therapeutics (UTHR) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for United Therapeutics (UTHR) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for United Therapeutics (UTHR) and Viatris (VTRS)
Metric	UTHR	VTRS
Total Return (1Y)	28.77%	108.98%
Total Return (3Y, Annualized)	37.63%	36.75%
Total Return (5Y, Annualized)	23.78%	11.59%

Risk Profile

Drawdown History

UTHR

VTRS

GSPC

United Therapeutics (UTHR) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for United Therapeutics (UTHR) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for United Therapeutics (UTHR) and Viatris (VTRS)
Metric	UTHR	VTRS
Volatility (1Y, Annualized)	35.00%	32.53%
Beta (5Y)	0.49	0.86
Max Drawdown (5Y)	-33.00%	-45.69%
Avg. Volume (3M)	694.55K	8.87M

Risk-Adjusted Performance

Risk-Return Positioning

UTHR and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for United Therapeutics (UTHR) and Viatris (VTRS)
Metric	UTHR	VTRS
Sharpe Ratio (1Y)	0.70	3.22
Sortino Ratio (1Y)	1.29	5.63

Profitability

ROE (TTM)

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile United Therapeutics (UTHR) reports 19.13%, ranking against industry peers normally.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.13%

Max: 109.18%
UTHR: 19.13%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max: 109.18%
Q3: 6.23%
VTRS: -4.21%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

United Therapeutics (UTHR) vs. Viatris (VTRS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile United Therapeutics (UTHR) reports 38.61%, ranking against industry peers normally.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.61%

UTHR: 38.61%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
VTRS: -4.13%
Q1: -4.14%
Min: -17.05%

United Therapeutics (UTHR) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

United Therapeutics (UTHR) at 28.99% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.99%

Max: 83.12%
UTHR: 28.99%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max: 83.12%
Q3: 14.77%
VTRS: 13.85%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

United Therapeutics (UTHR) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for United Therapeutics (UTHR) and Viatris (VTRS)
Metric	UTHR	VTRS
ROE (TTM)	19.13%	-4.21%
ROA (TTM)	10.91%	2.91%
Net Margin (TTM)	38.61%	-4.13%
Operating Margin (TTM)	28.99%	13.85%
Gross Margin (TTM)	86.34%	41.13%

Growth

Revenue Growth

United Therapeutics (UTHR) at 10.61% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.

United Therapeutics (UTHR) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: United Therapeutics (UTHR) reports EPS growth of 13.07%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.

United Therapeutics (UTHR) vs. Viatris (VTRS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for United Therapeutics (UTHR) and Viatris (VTRS)
Metric	UTHR	VTRS
Revenue Growth (YoY)	10.61%	-2.98%
Revenue Growth (3Y CAGR)	18.02%	-4.20%
EPS Growth (YoY)	13.07%	--
EPS Growth (3Y CAGR)	22.92%	--

Financial Strength

Current Ratio (MRQ)

United Therapeutics (UTHR) at 4.61 keeps current ratio within its industry’s typical mid-range, while Viatris (VTRS) at 1.55 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for VTRS.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.61

Max: 25.13
Q3: 12.13
Median: 5.52
UTHR: 4.61
Q1: 2.47
Min: 0.10

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
VTRS: 1.55
Min: 0.10

United Therapeutics (UTHR) vs. Viatris (VTRS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Viatris (VTRS) carries debt-to-equity ratio of 0.99 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
UTHR: --

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max: 1.42
VTRS: 0.99
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

United Therapeutics (UTHR) vs. Viatris (VTRS): UTHR does not report debt-to-equity ratio, so it has no value marker; VTRS is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for United Therapeutics (UTHR) and Viatris (VTRS)
Metric	UTHR	VTRS
Current Ratio (MRQ)	4.61	1.55
Debt / Equity (MRQ)	--	0.99
Net Debt / EBITDA	-1.53	2.64

Dividends

Dividend Yield (TTM)

United Therapeutics (UTHR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS: 2.53%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

United Therapeutics (UTHR) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; United Therapeutics (UTHR) pays no dividend (payout 0.00%).

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS: 960.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

United Therapeutics (UTHR) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for United Therapeutics (UTHR) and Viatris (VTRS)
Metric	UTHR	VTRS
Dividend Yield (TTM)	0.00%	2.53%
Dividend Payout Ratio (TTM)	0.00%	960.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: United Therapeutics (UTHR) trades at 21.22 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.22

Max: 85.34
Q3: 43.46
Median: 26.69
UTHR: 21.22
Q1: 13.30
Min: 0.07

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
VTRS: --

United Therapeutics (UTHR) vs. Viatris (VTRS): VTRS does not report P/E ratio, so it has no value marker; UTHR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while United Therapeutics (UTHR) at 7.51 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.51

Max: 58.18
Q3: 25.77
UTHR: 7.51
Median: 7.30
Q1: 3.01
Min: 0.01

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
VTRS: 1.55
Min: 0.01

United Therapeutics (UTHR) vs. Viatris (VTRS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile against book while United Therapeutics (UTHR) at 3.80 is valued near its industry’s middle — VTRS is cheaper on assets, though weigh it against ROE and asset quality.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.80

Max: 13.53
Q3: 6.54
UTHR: 3.80
Median: 3.25
Q1: 1.69
Min: -5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
VTRS: 1.67
Min: -5.59

United Therapeutics (UTHR) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for United Therapeutics (UTHR) and Viatris (VTRS)
Metric	UTHR	VTRS
P/E Ratio (TTM)	21.22	--
P/S Ratio (TTM)	7.51	1.55
P/B Ratio (MRQ)	3.80	1.67
Free Cash Flow Yield (TTM)	1.90%	13.84%